Home>Research>1195P – Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC

US Oncology Research Publications

« Back to All Resources

Poster
Lung
Treatment

1195P – Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC

Excellence in Cancer Care has a Network

As a national network of multi-specialty industry peers, we are dedicated to bringing innovation to local oncology care. We have the backing and resources to offer practices access to capital for expansion, innovative clinical trials through Sarah Cannon Research Institute, and the purchasing power and best-in-class contracting capabilities of Unity Group Purchasing Organization.

Join Our Network

Learn more about our commitment to enabling better cancer care through an integrated and supportive network that helps local practices maintain their independence and prosper.